drugset
drugset / Trial / NCT04999800

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

NCT04999800 ↗

Phase 2 Unknown 20 enrolled Shi Yuankai
NaSingle-groupOpen-labelTreatment

Summary

This trial is main evaluate the efficacy and safety of Pembrolizumab combined with Anlotinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma with CPS≥1

Timeline

Start
2021-07-18
Primary completion
2023-01-01
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

head and neck squamous cell carcinoma